| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers B > Headlines for BioMarin Pharmaceutical Inc. > News item |
BioMarin establishes commercial operations in Europe, names VP
By Lisa Kerner
Erie, Pa., Jan. 10 - BioMarin Pharmaceutical Inc. announced it has established commercial operations in Europe in anticipation of receiving European marketing approval for Naglazyme (galsulfase), an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
William E. Aliski has been appointed vice president and general manager of European operations, responsible for overseeing European commercialization efforts. Prior to joining BioMarin, Aliski was vice president of commercial operations at Transkaryotic Therapies, a biotechnology company. In this role, Aliski managed worldwide drug distribution, inventory management and patient support for the company's lead product, Replagal. Aliski previously worked at Genzyme Corp.
"We are pleased that Mr. Aliski has joined the BioMarin team and believe that his experience in the global commercialization of products for rare diseases further positions us for a successful European commercial launch of Naglazyme for MPS VI, pending final regulatory approval," Steve Aselage, senior vice president of global commercial operations said in a company news release. "With BioMarin Europe now in place, we look forward to commencing our first European product launch and to making Naglazyme available to the European MPS VI community in the not too distant future."
BioMarin, based in Novato, California, develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
BioMarin Europe Ltd. is headquartered in London, with branch offices located in Spain, Switzerland and Italy.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.